AFT Pharmaceuticals Limited (NZE:AFT)

Market Cap	295.72M
Revenue (ttm)	208.02M
Net Income (ttm)	11.96M
Shares Out	104.87M
EPS (ttm)	0.11
PE Ratio	25.64
Forward PE	18.11
Dividend	0.02 (0.65%)
Ex-Dividend Date	Jun 18, 2025

Volume	948
Average Volume	16,208
Open	2.820
Previous Close	2.780
Day's Range	2.820 - 2.820
52-Week Range	2.370 - 3.360
Beta	0.31
RSI	67.28
Earnings Date	Nov 21, 2025

About AFT Pharmaceuticals

AFT Pharmaceuticals Limited, together with its subsidiaries, develops, markets, and distributes pharmaceutical products in New Zealand, Australia, Asia, and internationally. The company offers patented, branded, and generic drugs; and products for use in the areas of allergy, cold and flu, digestive health, eye care, first aid, pain management, skin care, vitamins, supplements, gastrointestinal, dermatology, and hospital. It has a research and development collaboration with Belgium’s Hyloris Pharmaceuticals to develop a novel innovative injecta...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 119
• Stock Exchange: New Zealand Stock Exchange
• Ticker Symbol: AFT

Financial Performance

In 2024, AFT Pharmaceuticals's revenue was 208.02 million, an increase of 6.45% compared to the previous year's 195.41 million. Earnings were 11.96 million, a decrease of -23.36%.